WO2009126688A3 - Novel compositions and methods for the treatment of immune related diseases - Google Patents

Novel compositions and methods for the treatment of immune related diseases Download PDF

Info

Publication number
WO2009126688A3
WO2009126688A3 PCT/US2009/039868 US2009039868W WO2009126688A3 WO 2009126688 A3 WO2009126688 A3 WO 2009126688A3 US 2009039868 W US2009039868 W US 2009039868W WO 2009126688 A3 WO2009126688 A3 WO 2009126688A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
methods
related diseases
immune related
novel compositions
Prior art date
Application number
PCT/US2009/039868
Other languages
French (fr)
Other versions
WO2009126688A2 (en
WO2009126688A8 (en
Inventor
Hilary Clark
Dan Eaton
Lino Gonzalez
Jane L. Grogan
Jason Hackney
Kristin D. Harden
Xin Yu
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020187012359A priority Critical patent/KR101924831B1/en
Priority to SI200931728T priority patent/SI2279412T1/en
Priority to EP09730709.4A priority patent/EP2279412B1/en
Priority to PL17152167T priority patent/PL3208612T3/en
Priority to BRPI0906550A priority patent/BRPI0906550B8/en
Priority to CN200980121734.2A priority patent/CN102057272B/en
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Priority to KR1020187034436A priority patent/KR20180132156A/en
Priority to KR1020167036368A priority patent/KR101855381B1/en
Priority to DK09730709.4T priority patent/DK2279412T3/en
Priority to KR1020107025044A priority patent/KR101692080B1/en
Priority to EP19181712.1A priority patent/EP3605088A1/en
Priority to PL09730709T priority patent/PL2279412T3/en
Priority to ES09730709.4T priority patent/ES2640533T3/en
Priority to AU2009233708A priority patent/AU2009233708B2/en
Priority to CN201910073153.1A priority patent/CN110082533B/en
Priority to MX2013010169A priority patent/MX364200B/en
Priority to MX2010011088A priority patent/MX2010011088A/en
Priority to CA2719189A priority patent/CA2719189C/en
Priority to EP17152167.7A priority patent/EP3208612B1/en
Priority to JP2011504145A priority patent/JP5770624B2/en
Publication of WO2009126688A2 publication Critical patent/WO2009126688A2/en
Publication of WO2009126688A3 publication Critical patent/WO2009126688A3/en
Publication of WO2009126688A8 publication Critical patent/WO2009126688A8/en
Priority to IL208285A priority patent/IL208285A0/en
Priority to IL228988A priority patent/IL228988A/en
Priority to AU2015202123A priority patent/AU2015202123B2/en
Priority to IL246293A priority patent/IL246293B/en
Priority to AU2017221784A priority patent/AU2017221784B2/en
Priority to IL264498A priority patent/IL264498B/en
Priority to AU2019257492A priority patent/AU2019257492A1/en
Priority to IL272817A priority patent/IL272817A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.
PCT/US2009/039868 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases WO2009126688A2 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
CN201910073153.1A CN110082533B (en) 2008-04-09 2009-04-08 Novel compositions and methods for treatment of immune-related diseases
EP09730709.4A EP2279412B1 (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases
PL17152167T PL3208612T3 (en) 2008-04-09 2009-04-08 Compositions and methods for the treatment of immune related diseases
BRPI0906550A BRPI0906550B8 (en) 2008-04-09 2009-04-08 Anti-tigit antibody, uses of an anti-tigit antibody, and in vitro methods to stimulate the cd226-pvr interaction and/or the cd96-pvr interaction, to enhance or stimulate the proliferation of a T cell or the release of proinflammatory cytokines by a dendritic cell, to enhance or stimulate the immune response of the T cell to enhance or stimulate the production of proinflammatory cytokines by a dendritic cell
CN200980121734.2A CN102057272B (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases
MX2013010169A MX364200B (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases.
KR1020187034436A KR20180132156A (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases
KR1020167036368A KR101855381B1 (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases
DK09730709.4T DK2279412T3 (en) 2008-04-09 2009-04-08 PRESENT UNKNOWN COMPOSITIONS AND PROCEDURES FOR TREATING IMMUNRATED DISEASES
KR1020107025044A KR101692080B1 (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases
SI200931728T SI2279412T1 (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases
PL09730709T PL2279412T3 (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases
ES09730709.4T ES2640533T3 (en) 2008-04-09 2009-04-08 Compositions and novel methods for the treatment of diseases related to immunity
AU2009233708A AU2009233708B2 (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases
EP19181712.1A EP3605088A1 (en) 2008-04-09 2009-04-08 Compositions and methods for the treatment of immune related diseases
KR1020187012359A KR101924831B1 (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases
MX2010011088A MX2010011088A (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases.
CA2719189A CA2719189C (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases
EP17152167.7A EP3208612B1 (en) 2008-04-09 2009-04-08 Compositions and methods for the treatment of immune related diseases
JP2011504145A JP5770624B2 (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases
IL208285A IL208285A0 (en) 2008-04-09 2010-09-21 Novel compositions and methods for the treatment of immune related diseases
IL228988A IL228988A (en) 2008-04-09 2013-10-21 Antibody compositions for the treatment of immune related diseases
AU2015202123A AU2015202123B2 (en) 2008-04-09 2015-04-24 Novel compositions and methods for the treatment of immune related diseases
IL246293A IL246293B (en) 2008-04-09 2016-06-16 Novel compositions and methods for the treatment of immune related diseases
AU2017221784A AU2017221784B2 (en) 2008-04-09 2017-08-30 Novel compositions and methods for the treatment of immune related diseases
IL264498A IL264498B (en) 2008-04-09 2019-01-28 Novel compositions and methods for the treatment of immune related diseases
AU2019257492A AU2019257492A1 (en) 2008-04-09 2019-10-31 Novel compositions and methods for the treatment of immune related diseases
IL272817A IL272817A (en) 2008-04-09 2020-02-20 Novel compositions and methods for the treatment of immune related diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12353008P 2008-04-09 2008-04-09
US61/123,530 2008-04-09
US19427108P 2008-09-26 2008-09-26
US61/194,271 2008-09-26

Publications (3)

Publication Number Publication Date
WO2009126688A2 WO2009126688A2 (en) 2009-10-15
WO2009126688A3 true WO2009126688A3 (en) 2009-12-10
WO2009126688A8 WO2009126688A8 (en) 2010-06-03

Family

ID=40873503

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/039868 WO2009126688A2 (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases

Country Status (18)

Country Link
US (5) US20090258013A1 (en)
EP (3) EP3605088A1 (en)
JP (7) JP5770624B2 (en)
KR (4) KR101855381B1 (en)
CN (3) CN110082533B (en)
AU (1) AU2009233708B2 (en)
BR (1) BRPI0906550B8 (en)
CA (3) CA3179151A1 (en)
DK (1) DK2279412T3 (en)
ES (2) ES2640533T3 (en)
HK (1) HK1211081A1 (en)
HU (1) HUE036780T2 (en)
IL (5) IL208285A0 (en)
MX (3) MX364200B (en)
PL (2) PL3208612T3 (en)
SG (2) SG10202112838YA (en)
SI (1) SI2279412T1 (en)
WO (1) WO2009126688A2 (en)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2357505T3 (en) 2002-09-11 2011-04-27 Genentech, Inc. COMPOSITION AND NEW PROCEDURES FOR THE TREATMENT OF IMMUNORELATED DISEASES.
CA3179151A1 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
HUE061002T2 (en) 2011-09-23 2023-04-28 Mereo Biopharma 5 Inc Vegf/dll4 binding agents and uses thereof
CA2892831A1 (en) * 2012-12-04 2014-06-12 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
RU2019129525A (en) 2013-07-16 2019-11-05 Дженентек, Инк. METHODS FOR TREATING CANCER USING ANTAGONISTS BINDING THE PD-1 AXIS AND TIGIT INHIBITORS
WO2015006811A2 (en) * 2013-07-19 2015-01-22 The Walter And Eliza Hall Institute Of Medical Research Diagnostic methods
JP2016530267A (en) * 2013-08-22 2016-09-29 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ Immune receptor modulation to treat cancer and viral infections
AU2014308552B2 (en) * 2013-08-22 2020-02-13 The Council Of The Queensland Institute Of Medical Research Immunoreceptor modulation for treating cancer and viral infections
EP3036258B1 (en) * 2013-08-22 2023-07-19 The Council of the Queensland Institute of Medical Research Immunoreceptor modulation for treating cancer and viral infections
CN103487572B (en) * 2013-10-08 2017-03-29 北京大学人民医院 Application of the folliculus helper T cell (Tfh) in autoimmune disease state of an illness early warning
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3119913B1 (en) * 2014-03-21 2021-01-06 The Brigham and Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
US9885021B2 (en) 2014-06-12 2018-02-06 Children's National Medical Center Generation of broadly-specific, virus-immune cells targeting multiple HIV antigens for preventive and therapeutic use
JP2017522311A (en) * 2014-07-16 2017-08-10 ジェネンテック， インコーポレイテッド Method for treating cancer using TIGIT inhibitor and anticancer agent
MY184288A (en) * 2014-08-19 2021-03-30 Merck Sharp & Dohme Llc Anti-tigit antibodies
AU2015343494A1 (en) * 2014-11-06 2017-04-27 Genentech, Inc. Combination therapy comprising OX40 binding agonists and TIGIT inhibitors
BR112017013385A2 (en) * 2014-12-23 2018-02-06 Bristol-Myers Squibb Company antibodies to tigit
MA41460A (en) 2015-02-03 2017-12-12 Oncomed Pharm Inc TNFRSF LIAISON AGENTS AND THEIR USES
SG11201706583PA (en) 2015-02-19 2017-09-28 Compugen Ltd Anti-pvrig antibodies and methods of use
EP3259597B1 (en) 2015-02-19 2022-04-06 Compugen Ltd. Pvrig polypeptides and methods of treatment
EP3875477A1 (en) 2015-04-17 2021-09-08 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
US11022615B2 (en) * 2015-05-04 2021-06-01 University Of Florida Research Foundation, Inc. Regulatory T-cells, method for their isolation and uses
TWI715587B (en) * 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Tigit-binding agents and uses thereof
UY36687A (en) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware ANTIBODIES AGAINST OX40 AND ITS USES
JO3620B1 (en) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers cancers
EP3334757A4 (en) * 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. Anti-tigit antibodies
CN107949573B (en) 2015-09-01 2022-05-03 艾吉纳斯公司 anti-PD-1 antibodies and methods of use thereof
JP6861418B2 (en) * 2015-09-02 2021-04-28 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド Antibodies specific for human T cell immunoglobulin and ITIM domain (TIGIT)
AU2016322934A1 (en) * 2015-09-14 2018-04-12 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
CR20180225A (en) * 2015-09-25 2018-07-09 Genentech Inc ANTI-TIGIT ANTIBODY AND METHODS OF USE
KR20180051651A (en) * 2015-10-01 2018-05-16 히트 바이오로직스, 인코퍼레이티드 Compositions and methods for adjacent I and II extracellular domains as heterologous chimeric proteins
EP3356413B1 (en) * 2015-10-01 2022-01-05 Potenza Therapeutics, Inc. Anti-tigit antigen-binding proteins and methods of use thereof
JO3555B1 (en) 2015-10-29 2020-07-05 Merck Sharp & Dohme Antibody neutralizing human respiratory syncytial virus
RU2756275C2 (en) 2016-03-01 2021-09-29 Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. Antibodies specific to human poliovirus receptor (pvr)
BR112018067458A2 (en) 2016-03-04 2019-01-02 Abmuno Therapeutics Llc antibodies to tigit
EA039540B1 (en) * 2016-03-25 2022-02-08 Онкомед Фармасьютикалс, Инк. Tigit-binding agents and uses thereof
JP2019521643A (en) 2016-04-15 2019-08-08 アルパイン イミューン サイエンシズ インコーポレイテッド CD80 variant immunoregulatory protein and uses thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
MX2018016364A (en) 2016-06-20 2019-11-28 Kymab Ltd Anti-pd-l1 antibodies.
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
PL3347379T3 (en) 2016-08-17 2020-05-18 Compugen Ltd. Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
WO2018041120A1 (en) * 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tigit
CN107815467B (en) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Preparation method and application of humanized gene modified animal model
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3548071A4 (en) 2016-11-30 2020-07-15 OncoMed Pharmaceuticals, Inc. Methods for treatment of cancer comprising tigit-binding agents
US10232053B2 (en) 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
KR102581439B1 (en) 2017-01-05 2023-09-21 카 메디컬 리미티드 SIRPalpha-41BBL fusion protein and method of using the same
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
CN110536693B (en) 2017-01-05 2023-12-22 卡尔医学有限公司 PD1-41BBL fusion proteins and methods of using the same
JOP20190203A1 (en) 2017-03-30 2019-09-03 Potenza Therapeutics Inc Anti-tigit antigen-binding proteins and methods of use thereof
WO2018195552A1 (en) 2017-04-21 2018-10-25 Sillajen, Inc. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
WO2018200430A1 (en) 2017-04-26 2018-11-01 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EP3618871A4 (en) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
SG10202111336RA (en) 2017-06-01 2021-11-29 Compugen Ltd Triple combination antibody therapies
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
MX2020000960A (en) 2017-07-27 2020-07-22 iTeos Belgium SA Anti-tigit antibodies.
CN111051347B (en) 2017-09-29 2021-12-21 江苏恒瑞医药股份有限公司 TIGIT antibody, antigen-binding fragment thereof, and medical use thereof
US11753458B2 (en) 2017-10-10 2023-09-12 Alpine Immune Sciences, Inc. CTLA-4 variant immunomodulatory proteins and uses thereof
CN107988255A (en) * 2017-10-20 2018-05-04 深圳市龙岗区妇幼保健院 A kind of method of definite ATR and ERK calmodulin binding domain CaMs
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
MX2020008795A (en) 2018-02-28 2020-10-08 Yuhan Corp Anti-tigit antibodies and uses thereof.
KR20200016114A (en) 2018-08-06 2020-02-14 선일이씨티 주식회사 Waste water advanced treatment system based on biological contact and circulation filtering
SG11202101429YA (en) 2018-08-23 2021-03-30 Seagen Inc Anti-tigit antibodies
AR117327A1 (en) 2018-12-20 2021-07-28 23Andme Inc ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THEM
CN110156888B (en) * 2019-05-13 2021-07-30 沣潮医药科技（上海）有限公司 Application of CD96 recombinant protein in preparation of pharmaceutical composition for immune diseases
EP4001308A4 (en) 2019-07-15 2023-08-23 Shanghai Junshi Biosciences Co., Ltd. Anti-tigit antibodies and application thereof
CN112625130B (en) 2019-09-24 2023-08-29 财团法人工业技术研究院 Anti-TIGIT antibodies and methods of use
KR20220070011A (en) 2019-09-27 2022-05-27 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 antigen binding protein
CN114746446A (en) * 2019-11-21 2022-07-12 百济神州有限公司 Methods of treating cancer using anti-OX 40 antibodies in combination with anti-TIGIT antibodies
CA3170025A1 (en) 2020-03-13 2021-09-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pvrig binding protein and its medical uses
CN113563470B (en) 2020-04-29 2023-02-10 广州昂科免疫生物技术有限公司 Antibody combined with TIGIT antigen and preparation method and application thereof
EP4157875A1 (en) 2020-06-02 2023-04-05 Arcus Biosciences, Inc. Antibodies to tigit
US20210395366A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
TW202216778A (en) 2020-07-15 2022-05-01 美商安進公司 Tigit and cd112r blockade
CN111763660A (en) * 2020-08-07 2020-10-13 南京大学 Recombinant oncolytic vaccinia virus and preparation method and application thereof
WO2022044010A1 (en) 2020-08-26 2022-03-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
CN116406292A (en) * 2020-10-09 2023-07-07 学校法人庆应义塾 Therapeutic agent for immune/inflammatory diseases
CN112294946B (en) * 2020-10-28 2023-02-10 中国人民解放军空军军医大学 Pharmaceutical application of soluble recombinant protein CD226-ECD in inhibition of allergic rhinitis asthma syndrome
TW202233248A (en) 2020-11-08 2022-09-01 美商西健公司 Combination therapy
US20240067720A1 (en) 2021-01-14 2024-02-29 Shanghai Junshi Biosciences Co., Ltd. Anti-tigit antibody pharmaceutical composition and application thereof
CN117136258A (en) 2021-03-31 2023-11-28 泷搌（上海）生物科技有限公司 Vectors and methods for screening for functional antigen binding proteins
CN117730097A (en) 2021-04-09 2024-03-19 思进公司 Methods of treating cancer with anti-TIGIT antibodies
TW202304965A (en) 2021-05-04 2023-02-01 美商艾吉納斯公司 Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof
TW202309078A (en) 2021-07-02 2023-03-01 美商建南德克公司 Methods and compositions for treating cancer
WO2023010094A2 (en) 2021-07-28 2023-02-02 Genentech, Inc. Methods and compositions for treating cancer
CA3224180A1 (en) 2021-07-28 2023-02-02 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
WO2023014360A1 (en) * 2021-08-05 2023-02-09 Octagon Therapeutics, Inc. Treatment and diagnosis of immune disorders relating to aberrant immune cells
WO2023040935A1 (en) 2021-09-15 2023-03-23 江苏恒瑞医药股份有限公司 Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
TW202328195A (en) 2021-09-15 2023-07-16 大陸商江蘇恆瑞醫藥股份有限公司 Proteins that specifically bind to pd-1 and the pharmaceutical use thereof
TW202321308A (en) 2021-09-30 2023-06-01 美商建南德克公司 Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063063A1 (en) * 1998-06-03 1999-12-09 Northwestern University Cellular proteins which mediate herpesvirus entry
WO2004024072A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2004024068A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
WO2004074324A2 (en) * 2003-02-24 2004-09-02 Xerion Pharmaceuticals Ag Modulation of the poliovirus receptor function
EP1516629A2 (en) * 1996-11-27 2005-03-23 Genentech, Inc. Humanized anti CD-11a antibodies
GB2408508A (en) * 2003-11-28 2005-06-01 Astrazeneca Ab Apolipoprotein antibodies
WO2005052005A1 (en) * 2003-11-21 2005-06-09 Schering Corporation Anti-igfr1 antibody therapeutic combinations
WO2006042240A2 (en) * 2004-10-08 2006-04-20 Wyeth Immunotherapy of autoimmune disorders
WO2006124667A2 (en) * 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1516629A (en) * 1924-11-25 Ernest blaker
US2408528A (en) * 1945-01-16 1946-10-01 Nassour Edward Race recording system
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63502716A (en) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー How to enhance glycoprotein stability
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
WO1989005859A1 (en) 1987-12-21 1989-06-29 The Upjohn Company Agrobacterium mediated transformation of germinating plant seeds
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
ATE144281T1 (en) 1989-04-28 1996-11-15 Rhein Biotech Proz & Prod Gmbh YEAST CELLS OF THE GENUS SCHWANNIOMYCES
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
ES2096590T3 (en) 1989-06-29 1997-03-16 Medarex Inc BI-SPECIFIC REAGENTS FOR AIDS THERAPY.
FR2649120B1 (en) 1989-06-30 1994-01-28 Cayla NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
DE69128350T2 (en) 1990-06-11 1998-03-26 Nexstar Pharmaceuticals Inc NUCLEIC ACID LIGANDS
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (en) 1991-11-25 2006-03-16 Enzon, Inc. Process for the preparation of multivalent antigen-binding proteins
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
JP3095175B2 (en) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
EP0616812B1 (en) 1993-03-24 1999-11-03 Berlex Biosciences Combination with anti-hormonal compounds and binding molecules for the treatment of cancer
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5989811A (en) 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5750345A (en) 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
WO1997033551A2 (en) 1996-03-15 1997-09-18 Millennium Pharmaceuticals Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
US6518033B1 (en) 1998-08-05 2003-02-11 The Research Foundation Of State University Of New York Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment
JP2004516227A (en) 1999-03-08 2004-06-03 ジェネンテック・インコーポレーテッド Compositions and methods for treating immune-related diseases
CA2368467A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 50 human secreted proteins
US7282570B2 (en) 1999-04-20 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2291198T3 (en) * 1999-07-20 2008-03-01 Genentech, Inc. COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF IMMUNOLOGICAL TYPE DISEASES.
US20080050809A1 (en) * 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
AU1220001A (en) 1999-10-20 2001-04-30 Zymogenetics Inc. Novel proteins and polynucleotides encoding them
US20040219521A1 (en) * 2000-01-21 2004-11-04 Tang Y. Tom Novel nucleic acids and polypeptides
IL151865A0 (en) 2000-03-31 2003-04-10 Genentech Inc Compositions and methods for detecting and quantifying gene expression
AU2001249673A1 (en) 2000-04-04 2001-10-15 Schering Corporation Isolated nucleic acids from micromonospora rosaria plasmid pmr2 and vectors made therefrom
MXPA02012106A (en) 2000-06-06 2003-06-06 Bristol Myers Squibb Co B7-related nucleic acids and polypeptides useful for immunomodulation.
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2002099062A2 (en) * 2001-06-04 2002-12-12 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
US20040101876A1 (en) * 2002-05-31 2004-05-27 Liat Mintz Methods and systems for annotating biomolecular sequences
AU2002366951A1 (en) 2001-12-10 2003-07-09 Nuvelo,Inc. Novel nucleic acids and polypeptides
AU2003211112A1 (en) 2002-02-13 2003-09-04 Incyte Corporation Secreted proteins
JP2005535290A (en) * 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド Compositions and methods for the treatment of immune related diseases
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
PT1537878E (en) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Immunopotentiating compositions
JP4395570B2 (en) * 2002-07-30 2010-01-13 独立行政法人産業技術総合研究所 Method for producing hydrogen by thermochemical decomposition of water
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
CN1720336A (en) * 2002-10-03 2006-01-11 健泰科生物技术公司 Use of A33 antigens and JAM-IT
US6925898B2 (en) * 2002-10-18 2005-08-09 Logitech Europe S.A. Variable sensor shaft retention apparatus
US7144032B2 (en) * 2003-09-09 2006-12-05 Autoliv Asp, Inc. Expandable pelvic side airbag
CN101035807A (en) * 2004-06-09 2007-09-12 泰勒公司 Diagnosis and treatment of SIGLEC-6 associated diseases
US7096772B2 (en) * 2004-08-30 2006-08-29 Caterpillar S.A.R.L. System and method for controlling hydraulic fluid flow
KR101498834B1 (en) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
JP2009538120A (en) 2006-04-13 2009-11-05 ザイモジェネティクス， インコーポレイテッド Tetramerized polypeptides and methods of use
US20100075377A1 (en) 2006-04-13 2010-03-25 West James W Tetramerizing polypeptides and methods of use
US20070243584A1 (en) 2006-04-13 2007-10-18 West James W Tetramerizing polypeptides and methods of use
WO2007124383A2 (en) 2006-04-19 2007-11-01 Oregon Health & Science University 1,1'-binaphthyl-based inhibitors of nad+-dependent deacetylase activity and sir2-family members
CA3179151A1 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
TWI686405B (en) 2008-12-09 2020-03-01 建南德克公司 Anti-pd-l1 antibodies and their use to enhance t-cell function
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
CN103168048B (en) 2010-06-09 2017-02-15 酶原遗传学有限公司 dimeric VSTM3 fusion proteins and related compositions and methods
EA026924B1 (en) 2011-08-01 2017-05-31 Дженентек, Инк. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
EP2812022B1 (en) 2012-02-06 2019-06-26 Providence Health & Services - Oregon Method of monitoring cancer treatment using ox40 agonists
PT2925350T (en) 2012-12-03 2019-03-25 Bristol Myers Squibb Co Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
CA2892831A1 (en) 2012-12-04 2014-06-12 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
CN103073644B (en) 2012-12-31 2014-03-12 中国科学技术大学 Specific anti-mouse TIGIT monoclonal antibody and preparation method, identification and application thereof
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2014151006A2 (en) 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
RU2019129525A (en) 2013-07-16 2019-11-05 Дженентек, Инк. METHODS FOR TREATING CANCER USING ANTAGONISTS BINDING THE PD-1 AXIS AND TIGIT INHIBITORS
EP3043819A4 (en) 2013-09-11 2017-04-05 Compugen Ltd. Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
CN106132439A (en) 2014-03-31 2016-11-16 豪夫迈·罗氏有限公司 Comprise antiangiogenic agent and OX40 combines the combination treatment of agonist
MA40682B1 (en) 2014-03-31 2020-01-31 Hoffmann La Roche Anti-ox40 antibodies and methods of use thereof
JP2017522311A (en) 2014-07-16 2017-08-10 ジェネンテック， インコーポレイテッド Method for treating cancer using TIGIT inhibitor and anticancer agent
MY184288A (en) 2014-08-19 2021-03-30 Merck Sharp & Dohme Llc Anti-tigit antibodies
BR112017006664A2 (en) 2014-10-03 2017-12-26 Novartis Ag combination therapies
AU2015343494A1 (en) 2014-11-06 2017-04-27 Genentech, Inc. Combination therapy comprising OX40 binding agonists and TIGIT inhibitors
BR112017013385A2 (en) 2014-12-23 2018-02-06 Bristol-Myers Squibb Company antibodies to tigit
UA124143C2 (en) 2015-05-20 2021-07-28 Янссен Байотек, Інк. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
TWI715587B (en) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Tigit-binding agents and uses thereof
CR20180225A (en) 2015-09-25 2018-07-09 Genentech Inc ANTI-TIGIT ANTIBODY AND METHODS OF USE
EP3548071A4 (en) 2016-11-30 2020-07-15 OncoMed Pharmaceuticals, Inc. Methods for treatment of cancer comprising tigit-binding agents
US11407830B2 (en) 2017-01-09 2022-08-09 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
CN111050788A (en) 2017-02-28 2020-04-21 西雅图基因公司 anti-TIGIT antibody
CA3059468A1 (en) 2017-04-27 2018-11-01 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
JP7391027B2 (en) 2018-02-26 2023-12-04 ジェネンテック， インコーポレイテッド Medication for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
AU2019375409A1 (en) 2018-11-05 2021-05-27 Merck Sharp & Dohme Llc Dosing regimen of anti-TIGIT antibody for treatment of cancer

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1516629A2 (en) * 1996-11-27 2005-03-23 Genentech, Inc. Humanized anti CD-11a antibodies
WO1999063063A1 (en) * 1998-06-03 1999-12-09 Northwestern University Cellular proteins which mediate herpesvirus entry
WO2004024072A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2004024068A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
WO2004074324A2 (en) * 2003-02-24 2004-09-02 Xerion Pharmaceuticals Ag Modulation of the poliovirus receptor function
WO2005052005A1 (en) * 2003-11-21 2005-06-09 Schering Corporation Anti-igfr1 antibody therapeutic combinations
GB2408508A (en) * 2003-11-28 2005-06-01 Astrazeneca Ab Apolipoprotein antibodies
WO2006042240A2 (en) * 2004-10-08 2006-04-20 Wyeth Immunotherapy of autoimmune disorders
WO2006124667A2 (en) * 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] 8 April 2008 (2008-04-08), XP002546273, Database accession no. Q495A1 *
OTA T ET AL: "COMPLETE SEQUENCING AND CHARACTERIZATION OF 21,243 FULL-LENGTH HUMAN CDNAS", NATURE GENETICS, NATURE PUBLISHING GROUP, NEW YORK, US, vol. 36, no. 1, 1 January 2004 (2004-01-01), pages 40 - 45, XP008055982, ISSN: 1061-4036 *
SETH S ET AL: "THE POLIOVIRUS RECEPTOR/CD155 IS A POTENTIAL MODULATOR OF THE T CELL RESPONSE", IMMUNOBIOLOGY, URBAN UND FISCHER VERLAG, DE, vol. 210, no. 6-8, 1 January 2005 (2005-01-01), pages 542, XP009074924, ISSN: 0171-2985 *

Also Published As

Publication number Publication date
CN102057272B (en) 2015-02-18
KR101924831B1 (en) 2018-12-05
WO2009126688A2 (en) 2009-10-15
IL272817A (en) 2020-04-30
JP6246158B2 (en) 2017-12-13
IL228988A0 (en) 2013-12-31
US11390678B2 (en) 2022-07-19
US20230098521A1 (en) 2023-03-30
EP3208612B1 (en) 2019-09-18
KR101692080B1 (en) 2017-01-02
ES2640533T3 (en) 2017-11-03
HUE036780T2 (en) 2018-07-30
IL208285A0 (en) 2010-12-30
IL264498A (en) 2019-02-28
MX2010011088A (en) 2010-11-05
JP2020114211A (en) 2020-07-30
SG10202112838YA (en) 2021-12-30
CA2719189A1 (en) 2009-10-15
DK2279412T3 (en) 2017-10-16
CN110082533A (en) 2019-08-02
HK1211081A1 (en) 2016-05-13
KR20170004019A (en) 2017-01-10
CN104655854A (en) 2015-05-27
JP2021180663A (en) 2021-11-25
EP2279412B1 (en) 2017-07-26
CN102057272A (en) 2011-05-11
MX364200B (en) 2019-04-16
PL2279412T3 (en) 2017-12-29
AU2009233708B2 (en) 2015-06-04
BRPI0906550A2 (en) 2015-07-07
US20200317773A1 (en) 2020-10-08
EP3208612A1 (en) 2017-08-23
US20090258013A1 (en) 2009-10-15
KR20180049227A (en) 2018-05-10
KR20180132156A (en) 2018-12-11
ES2758126T3 (en) 2020-05-04
IL228988A (en) 2017-02-28
IL246293A0 (en) 2016-07-31
CA2905334A1 (en) 2009-10-15
AU2009233708A1 (en) 2009-10-15
IL264498B (en) 2020-07-30
JP2011523034A (en) 2011-08-04
CN110082533B (en) 2023-01-10
SI2279412T1 (en) 2017-10-30
EP2279412A2 (en) 2011-02-02
JP2017215332A (en) 2017-12-07
KR20100135892A (en) 2010-12-27
CA3179151A1 (en) 2009-10-15
WO2009126688A8 (en) 2010-06-03
KR101855381B1 (en) 2018-05-09
PL3208612T3 (en) 2020-03-31
MX2018009945A (en) 2020-09-02
JP2019054793A (en) 2019-04-11
US20170145093A1 (en) 2017-05-25
EP3605088A1 (en) 2020-02-05
JP2015178504A (en) 2015-10-08
SG10201402815VA (en) 2014-09-26
IL246293B (en) 2019-02-28
JP5770624B2 (en) 2015-08-26
BRPI0906550B1 (en) 2021-11-30
JP2023055712A (en) 2023-04-18
US9499596B2 (en) 2016-11-22
CA2719189C (en) 2020-08-04
BRPI0906550B8 (en) 2022-01-11
US20130251720A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2011106297A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2012058393A3 (en) Dkk1 antibodies and methods of use
WO2012047631A3 (en) Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
WO2009129246A3 (en) Compositions and methods for preparing and using same
MY164731A (en) Compound
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
WO2011025978A3 (en) Methods of treatment using anti-oxidized ldl antibodies
WO2012037116A3 (en) Genetic variations associated with common variable immunodeficiency (cvid) and methods of use thereof
WO2010065586A3 (en) Preparation of capecitabine
WO2008112840A3 (en) Novel composition and methods for the treatment of immune related diseases
WO2011008947A3 (en) Treatment and diagnosis of immune disorders
MX339361B (en) Alternan derivatives.
EP2357252A4 (en) Methods and compositions for the treatment and diagnosis of haemorrhagic conversion
WO2010085799A9 (en) Compositions and method for the treatment of parkinson's disease
EP2369936A4 (en) Compositions and methods for the treatment and prevention of lens fibrotic diseases
WO2009146463A3 (en) Variant hhip1 protein and methods and uses thereof
AU2019257492A1 (en) Novel compositions and methods for the treatment of immune related diseases
WO2011084523A3 (en) Ulk1 compositions, inhibitors, screening and methods of use
WO2008037497A3 (en) Galectin-2 for the treatment of inflammatory diseases of the skin
WO2011156820A9 (en) Compositions, methods and uses for treatment of type 1 diabetes
WO2009151495A3 (en) Oxazole compounds, compositions and methods of use
WO2011127482A3 (en) Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980121734.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09730709

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009233708

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 6588/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2719189

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/011088

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011504145

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2009233708

Country of ref document: AU

Date of ref document: 20090408

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107025044

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2009730709

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009730709

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0906550

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101001

WWE Wipo information: entry into national phase

Ref document number: 246293

Country of ref document: IL